LKLaura C. Kim

Laura C. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura C. Kim has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeting Branched-Chain Amino Acid Transamination Sensitizes Clear-Cell Renal Cell Carcinoma to Glutaminase Inhibition

    by Nathan J. Coffey, Sara M. Demczyszyn, Yizheng Xue, Zian Zhang, Nicolas Skuli, Nicholas P. Lesner, Romain Riscal, Yanqing Jiang, Xu Han, Madeleine Carens, et al.

    Metabolic reprogramming is a well-described hallmark of clear-cell renal cell carcinoma (ccRCC). Gene copy-number variation and altered gene expression data suggest that enhanced branched-chain amino acid (BCAA) transamination and reduced BCAA oxidation are highly selected traits in ccRCC. Surprisingly, we found that genetic modulation of BCAA oxidation had little effect on experimental ccRCC cell growth in vitro and in vivo. In contrast, BCAA transamination in ccRCC cells was essential for the generation of glutamate (GLU)-derived glutathione (GSH) and cell viability when glutamine was limiting. Thus, BCAA transamination conferred resistance to states of low glutamine or treatment with the glutaminase (GLS) inhibitor CB-839 by providing GSH independent of glutamine breakdown. Targeting BCAA transamination in vitro and in vivo sensitized ccRCC to CB-839–mediated GLS inhibition by decreasing GSH biosynthesis and redox homeostasis. These findings reveal that BCAA transamination maintains critical GLU and GSH levels in glutamine-deprived ccRCC, explaining why CB-839 treatment has been ineffective in ccRCC clinical trials, and demonstrate an approach to treat ccRCC by targeting BCAA transamination to create a vulnerability to GLS inhibition. Significance: Branched-chain amino acid transamination maintains essential glutamate and glutathione levels in glutamine-deprived clear cell renal cell carcinoma and can be targeted to sensitize tumors to glutaminase inhibition by impairing redox homeostasis.

  • Open Access

    Activated ATF6α is a hepatic tumour driver restricting immunosurveillance

    by Xin Li, Cynthia Lebeaupin, Aikaterini Kadianaki, Clementine Druelle-Cedano, Niklas Vesper, Charlotte Rennert, Júlia Huguet-Pradell, Borja Gomez Ramos, Chaofan Fan, Robert Stefan Piecyk, et al.

    Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality and there are limited therapies 1 . Although endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR transducer ATF6α remains unclear 2 . Here we demonstrate the function of ATF6α as an ER-stress-inducing tumour driver and metabolic master regulator restricting cancer immunosurveillance for HCC, in contrast to its well-characterized role as an adaptive response to ER stress 3 . ATF6α activation in human HCC is significantly correlated with an aggressive tumour phenotype, characterized by reduced patient survival, enhanced tumour progression and local immunosuppression. Hepatocyte-specific ATF6α activation in mice induced progressive hepatitis with ER stress, immunosuppression and hepatocyte proliferation. Concomitantly, activated ATF6α increased glycolysis and directly repressed the gluconeogenic enzyme FBP1 by binding to gene regulatory elements. Restoring FBP1 expression limited ATF6α-activation-related pathologies. Prolonged ATF6α activation in hepatocytes triggered hepatocarcinogenesis, intratumoural T cell infiltration and nutrient-deprived immune exhaustion. Immune checkpoint blockade (ICB) 4 restored immunosurveillance and reduced HCC. Consistently, patients with HCC who achieved a complete response to immunotherapy displayed significantly increased ATF6α activation compared with those with a weaker response. Targeting Atf6 through germline ablation, hepatocyte-specific ablation or therapeutic hepatocyte delivery of antisense oligonucleotides dampened HCC in preclinical liver cancer models. Thus, prolonged ATF6α activation drives ER stress, leading to glycolysis-dependent immunosuppression in liver cancer and sensitizing to ICB. Our findings suggest that persistently activated ATF6α is a tumour driver, a potential stratification marker for ICB response and a therapeutic target for HCC.


  • Open Access

    Author Correction: Disrupting cellular memory to overcome drug resistance

    by Guillaume Harmange, Raúl A. Reyes Hueros, Dylan L. Schaff, Benjamin Emert, Michael Saint-Antoine, Laura C. Kim, Zijian Niu, Shivani Nellore, Mitchell E. Fane, Gretchen M. Alicea, et al.

  • Open Access

    Disrupting cellular memory to overcome drug resistance

    by Guillaume Harmange, Raúl A. Reyes Hueros, Dylan L. Schaff, Benjamin Emert, Michael Saint-Antoine, Laura C. Kim, Zijian Niu, Shivani Nellore, Mitchell E. Fane, Gretchen M. Alicea, et al.

    Gene expression states persist for varying lengths of time at the single-cell level, a phenomenon known as gene expression memory. When cells switch states, losing memory of their prior state, this transition can occur in the absence of genetic changes. However, we lack robust methods to find regulators of memory or track state switching. Here, we develop a lineage tracing-based technique to quantify memory and identify cells that switch states. Applied to melanoma cells without therapy, we quantify long-lived fluctuations in gene expression that are predictive of later resistance to targeted therapy. We also identify the PI3K and TGF-β pathways as state switching modulators. We propose a pretreatment model, first applying a PI3K inhibitor to modulate gene expression states, then applying targeted therapy, which leads to less resistance than targeted therapy alone. Together, we present a method for finding modulators of gene expression memory and their associated cell fates.


  • Open Access

    Data from Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer

    by Wenqiang Song, Laura C. Kim, Wei Han, Yuan Hou, Deanna N. Edwards, Shan Wang, Timothy S. Blackwell, Feixiong Cheng, Dana M. Brantley-Sieders, Jin Chen

    EphA2 receptor tyrosine kinase (RTK) is often expressed at high levels in cancer and has been shown to regulate tumor growth and metastasis across multiple tumor types, including non–small cell lung cancer. A number of signaling pathways downstream of EphA2 RTK have been identified; however, mechanisms of EphA2 proximal downstream signals are less well characterized. In this study, we used a yeast-two-hybrid screen to identify phospholipase C gamma 1 (PLCγ1) as a novel EphA2 interactor. EphA2 interacts with PLCγ1 and the kinase activity of EphA2 was required for phosphorylation of PLCγ1. In human lung cancer cells, genetic or pharmacologic inhibition of EphA2 decreased phosphorylation of PLCγ1 and loss of PLCγ1 inhibited tumor cell growth in vitro. Knockout of PLCγ1 by CRISPR-mediated genome editing also impaired tumor growth in a KrasG12D-p53-Lkb1 murine lung tumor model. Collectively, these data show that the EphA2-PLCγ1 signaling axis promotes tumor growth of lung cancer and provides rationale for disruption of this signaling axis as a potential therapeutic option.Implications:The EphA2-PLCG1 signaling axis promotes tumor growth of non–small cell lung cancer and can potentially be targeted as a therapeutic option.

  • Open Access

    Data from Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer

    by Wenqiang Song, Laura C. Kim, Wei Han, Yuan Hou, Deanna N. Edwards, Shan Wang, Timothy S. Blackwell, Feixiong Cheng, Dana M. Brantley-Sieders, Jin Chen

    EphA2 receptor tyrosine kinase (RTK) is often expressed at high levels in cancer and has been shown to regulate tumor growth and metastasis across multiple tumor types, including non–small cell lung cancer. A number of signaling pathways downstream of EphA2 RTK have been identified; however, mechanisms of EphA2 proximal downstream signals are less well characterized. In this study, we used a yeast-two-hybrid screen to identify phospholipase C gamma 1 (PLCγ1) as a novel EphA2 interactor. EphA2 interacts with PLCγ1 and the kinase activity of EphA2 was required for phosphorylation of PLCγ1. In human lung cancer cells, genetic or pharmacologic inhibition of EphA2 decreased phosphorylation of PLCγ1 and loss of PLCγ1 inhibited tumor cell growth in vitro. Knockout of PLCγ1 by CRISPR-mediated genome editing also impaired tumor growth in a KrasG12D-p53-Lkb1 murine lung tumor model. Collectively, these data show that the EphA2-PLCγ1 signaling axis promotes tumor growth of lung cancer and provides rationale for disruption of this signaling axis as a potential therapeutic option.Implications:The EphA2-PLCG1 signaling axis promotes tumor growth of non–small cell lung cancer and can potentially be targeted as a therapeutic option.

  • Open Access

    Supplementary Figures from Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer

    by Wenqiang Song, Laura C. Kim, Wei Han, Yuan Hou, Deanna N. Edwards, Shan Wang, Timothy S. Blackwell, Feixiong Cheng, Dana M. Brantley-Sieders, Jin Chen

    Supplemental Figure 1. Densitometry analysis of p-PLCγ1and p-EphA2 inhibition by ALWand human lung TMA analysis. Supplemental Figure 2. sgPLCG1 mismatch detection.

  • Open Access

    Supplementary Figures from Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer

    by Wenqiang Song, Laura C. Kim, Wei Han, Yuan Hou, Deanna N. Edwards, Shan Wang, Timothy S. Blackwell, Feixiong Cheng, Dana M. Brantley-Sieders, Jin Chen

    Supplemental Figure 1. Densitometry analysis of p-PLCγ1and p-EphA2 inhibition by ALWand human lung TMA analysis. Supplemental Figure 2. sgPLCG1 mismatch detection.

  • Top Cited Papers

    Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer

    by Deanna N. Edwards, Verra M. Ngwa, Ariel L. Raybuck, Shan Wang, Yoonha Hwang, Laura C. Kim, Sung Hoon Cho, Yeeun Paik, Qingfei Wang, Siyuan Zhang, et al.

    Rapidly proliferating tumor and immune cells need metabolic programs that support energy and biomass production. The amino acid glutamine is consumed by effector T cells and glutamine-addicted triple-negative breast cancer (TNBC) cells, suggesting that a metabolic competition for glutamine may exist within the tumor microenvironment, potentially serving as a therapeutic intervention strategy. Here, we report that there is an inverse correlation between glutamine metabolic genes and markers of T cell–mediated cytotoxicity in human basal-like breast cancer (BLBC) patient data sets, with increased glutamine metabolism and decreased T cell cytotoxicity associated with poor survival. We found that tumor cell–specific loss of glutaminase (GLS), a key enzyme for glutamine metabolism, improved antitumor T cell activation in both a spontaneous mouse TNBC model and orthotopic grafts. The glutamine transporter inhibitor V-9302 selectively blocked glutamine uptake by TNBC cells but not CD8+ T cells, driving synthesis of glutathione, a major cellular antioxidant, to improve CD8+ T cell effector function. We propose a “glutamine steal” scenario, in which cancer cells deprive tumor-infiltrating lymphocytes of needed glutamine, thus impairing antitumor immune responses. Therefore, tumor-selective targeting of glutamine metabolism may be a promising therapeutic strategy in TNBC.